Immatics (NASDAQ:IMTX) Hits New 1-Year High at $13.53

Immatics (NASDAQ:IMTXGet Free Report)’s stock price hit a new 52-week high on Wednesday . The company traded as high as $13.53 and last traded at $13.41, with a volume of 499593 shares. The stock had previously closed at $12.42.

Wall Street Analyst Weigh In

Separately, Mizuho raised their target price on shares of Immatics from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, May 16th.

Read Our Latest Analysis on Immatics

Immatics Price Performance

The stock has a market capitalization of $1.13 billion, a P/E ratio of -12.35 and a beta of 0.73. The stock’s fifty day moving average is $10.77 and its two-hundred day moving average is $10.86.

Immatics (NASDAQ:IMTXGet Free Report) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.70. Immatics had a negative net margin of 107.80% and a negative return on equity of 29.36%. The firm had revenue of $32.87 million during the quarter, compared to analyst estimates of $17.76 million. Analysts expect that Immatics will post -1.26 EPS for the current year.

Hedge Funds Weigh In On Immatics

A number of hedge funds have recently modified their holdings of IMTX. Exchange Traded Concepts LLC raised its holdings in Immatics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 11,501 shares of the company’s stock valued at $121,000 after buying an additional 2,916 shares in the last quarter. Nan Fung Group Holdings Ltd acquired a new stake in shares of Immatics in the first quarter valued at about $165,000. ADAR1 Capital Management LLC acquired a new stake in shares of Immatics in the fourth quarter valued at about $232,000. Jump Financial LLC acquired a new stake in shares of Immatics in the third quarter valued at about $469,000. Finally, Trexquant Investment LP grew its position in shares of Immatics by 4.2% in the fourth quarter. Trexquant Investment LP now owns 44,773 shares of the company’s stock valued at $471,000 after purchasing an additional 1,801 shares during the last quarter. 64.41% of the stock is owned by institutional investors and hedge funds.

About Immatics

(Get Free Report)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

See Also

Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with's FREE daily email newsletter.